市场调查报告书
商品编码
1497579
犬异位性皮肤炎市场:按产品、过敏原、给药途径、分销管道和最终用户 - 全球预测 2024-2030Canine Atopic Dermatitis Market by Product (Antihistamines, Glucocorticoids, Immunosuppressants), Allergen (Dander, Microorganisms, Mites), Route of Administration, Distribution Channel, End-User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
犬异位性皮肤炎市场规模预计到2023年为15.7亿美元,2024年达到16.9亿美元,预计到2030年将达到27.6亿美元,复合年增长率为8.40%。
犬异位性皮肤炎(CAD)是犬类的一种慢性搔痒性发炎皮肤病,由异常的免疫反应或对环境过敏原的先天倾向所引起。由于生活方式的改变以及宠物健康管理意识的提高,养狗人数不断增加,目前世界各地都在进行CAD治疗。近年来,诊断技术的进步导致了这种慢性疾病的有效治疗方法的建立。然而,与诊断和长期管理相关的高成本可能成为饲主的障碍,限制了新疗法和疗法的引入。在犬异位性皮肤炎市场中,监管障碍可能会阻碍新疗法的开发和批准。为了确保各种 CAD 治疗方法的商业化,公司正在进行创新研究,提供具有成本效益的治疗方法,同时确保了解不断变化的法规。次世代定序(NGS)等新兴技术正在帮助识别导致犬异位性皮肤炎易感性和治疗反应的遗传因素,为个人化治疗方法提供有价值的资讯。
主要市场统计 | |
---|---|
基准年[2023] | 15.7亿美元 |
预测年份 [2024] | 16.9亿美元 |
预测年份 [2030] | 27.6亿美元 |
复合年增长率(%) | 8.40% |
区域洞察
由于兽药市场的显着开拓以及老牌公司为提供新一代治疗方法而不断进行的研究工作,美洲的 CAD 市场正在不断发展。在美国和加拿大,越来越多的饲主开始意识到 CAD 对宠物生活品质的影响,该地区对有效治疗的需求正在迅速增加。在亚洲国家,尤其是在都市化地区,CAD 的盛行率正在显着增加。然而,兽医皮肤病学认知度低和市场结构分散给企业扩张到该地区带来了挑战。儘管大型跨国公司在亚洲开展业务,但它们必须与提供经济高效的 CAD 治疗选择的中小型本地製造商竞争。欧洲市场是一个成熟的兽医皮肤病市场,其特点是老字型大小企业提供专门的诊断工具和治疗解决方案来管理 CAD。大型製药企业之间的合作正在开发一种突破性的单株抗体疗法,以减轻与异位性皮肤炎相关的搔痒。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在犬异位性皮肤炎市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对犬异位性皮肤炎市场中供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该行业竞争力的宝贵见解,包括研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对犬异位性皮肤炎市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[190 Pages Report] The Canine Atopic Dermatitis Market size was estimated at USD 1.57 billion in 2023 and expected to reach USD 1.69 billion in 2024, at a CAGR 8.40% to reach USD 2.76 billion by 2030.
Canine atopic dermatitis (CAD) is a chronic, pruritic inflammatory skin condition in dogs due to an inherited predisposition to aberrant immune responses and environmental allergens. Increasing dog ownership rates with changing lifestyles and greater awareness about pet healthcare have led to the adoption of CAD treatments worldwide. Recent years have observed advancements in diagnostic techniques, enabling effective treatment solutions for this chronic condition. However, high costs associated with diagnostics and long-term management can also be a barrier for pet owners, limiting the adoption of new treatments and therapies. Regulatory hurdles can impede the development and approval of novel therapeutics in the canine atopic dermatitis market. Companies are working on innovative research to offer cost-effective treatments while ensuring knowledge of the changing regulations to ensure the commercialization of diverse CAD treatments. Emerging technologies such as next-generation sequencing (NGS) could help identify genetic factors contributing to canine atopic dermatitis susceptibility or treatment response, providing valuable information for personalized therapy approaches.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.57 billion |
Estimated Year [2024] | USD 1.69 billion |
Forecast Year [2030] | USD 2.76 billion |
CAGR (%) | 8.40% |
Regional Insights
The Americas CAD market is advancing, driven by huge developments in veterinary medicine and ongoing research activities by established companies to offer new-generation treatments. With an increasing number of pet owners becoming aware of CAD's impact on their pets' quality of life in the U.S. and Canada, demand for effective treatments has surged in the region. The prevalence of CAD is significantly rising across Asian countries, particularly in urbanized regions. However, limited awareness about veterinary dermatology and fragmented market structures present challenges to companies catering to this region. Major global players have established a presence in Asia; however they need to contend with smaller local manufacturers that offer cost-effective alternatives for CAD treatments. The European market presents a mature landscape for veterinary dermatology, characterized by well-established companies offering specialized diagnostic tools and therapeutic solutions for managing CAD. Partnerships between leading pharmaceutical firms have led to the development of innovative monoclonal antibody therapies, which offer targeted relief from pruritus associated with atopic dermatitis.
Market Insights
The market dynamics represent an ever-changing landscape of the Canine Atopic Dermatitis Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Canine Atopic Dermatitis Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Canine Atopic Dermatitis Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Zoetis Opens New State-of-the-Art Facility in Lincoln, NE, USA
Zoetis conducted the opening of its state-of-the-art mAbs expansion facility in Lincoln, Nebraska, and the facility comprises manufacturing, testing, and support buildings, employing a dedicated workforce of nearly 950 employees who work around the clock year-round. The facility is responsible for the production of animal health biologics, biopharmaceuticals, and pharmaceutical products tailoring to meet the specific needs of animals. [Published On: 2023-08-09]
Zoetis Announces FDA Approval of Apoquel Chewable (oclacitinib chewable tablet) for Control of Pruritus Associated With Allergic Dermatitis and Control of Atopic Dermatitis in Dogs
Zoetis Inc. announced that the FDA approved Apoquel chewable tablet for controlling pruritus associated with allergic dermatitis and atopic dermatitis in dogs aged 12 months and above. This chewable treatment is the first of its kind in the U.S., offering comparable efficacy to the original Apoquel (oclacitinib tablet). [Published On: 2023-06-13]
ILC Therapeutics entered into a strategic R&D partnership with Dechra Pharmaceuticals
UK-based biotech company ILC Therapeutics announced a research and development partnership with Dechra Pharmaceuticals. The collaboration aims to develop ILC's Caniferon product to treat canine atopic dermatitis. This collaboration contributes to their existing pipeline and may lead to a full development program and can enable the effective development of an effective treatment for canine atopic dermatitis. [Published On: 2023-05-24]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Canine Atopic Dermatitis Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Canine Atopic Dermatitis Market, highlighting leading vendors and their innovative profiles. These include AB Science SA, AbbVie, Inc., Agrolabo SpA, Bimeda, Inc., Bioceltix JSC, Bioiberica S.A.U., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Deep Marine Collagen, Elanco Animal Health Incorporated, Farnam Companies, Inc., IDEXX Laboratories, Inc., Incyte Corporation, Kemin Industries, Inc., LEO Pharma A/S, Merck & Co. Inc., Natural Dog Company, Nextmune, Nippon Zenyaku Kogyo Co., Ltd., Novartis AG, Ourofino Animal Health, Pfizer Inc, Phibro Animal Health Corporation, Regeneron Pharmaceuticals, Inc, Saiba Animal Health AG, Toray Industries Inc., Vetoquinol S.A., Virbac Corporation, Zinpro Corporation, Zoetis Inc., and Zymox by Pet King Brands LLC.
Market Segmentation & Coverage